Cardiovascular Hazards of Abacavir- Versus Tenofovir-Containing Antiretroviral Therapies: Insights From an Analysis of the REPRIEVE Trial Cohort

By sjmartinez • April 10, 2025

Davies Smith E, Malvestutto C, Ribaudo HJ, Fichtenbaum CJ, Aberg JA, Watanabe M, Bloomfield GS, Currier JS, Chu SM, Fitch KV, Diggs MR, Bedimo R, Valencia J, Gomez-Ayerbe C, Brar I, Madruga JV, Lu MT, Douglas PS, Zanni MV, Grinspoon SK. Cardiovascular Hazards of Abacavir- Versus Tenofovir-Containing Antiretroviral Therapies: Insights From an Analysis of the REPRIEVE Trial Cohort. Open Forum Infect Dis. 2025 Mar 21;12(4):ofaf177. doi: 10.1093/ofid/ofaf177. PMID: 40207047; PMCID: PMC11979587.

Tags: abacavir, antiretroviral therapy, Infectious Diseases, major adverse cardiovascular events, Publications, REPRIEVE, Tenofovir

No evidence of pitavastatin effect on muscle area or density among people with HIV

Erlandson KM, Umbleja T, Ribaudo HJ, Lu MT, Taron J, Diggs MR, Douglas PS, Fitch KV, Fichtenbaum CJ, Zanni MV, Aberg JA, Rodriguez-Barradas MC, Breaux[...]

Baseline predictors for 28-day COVID-19 severity and mortality among hospitalized patients: results from the IMPACC study

Hou J, Haslund-Gourley B, Diray-Arce J, Hoch A, Rouphael N, Becker PM, Augustine AD, Ozonoff A, Guan L, Kleinstein SH, Peters B, Reed E, Altman[...]

Prostate cancer incidence and outcomes among Vietnam veterans receiving care in the Veterans Health Administration

Green-Lott AY, Wadhwa A, Bailey AV, Kwan L, Haroldsen CL, Shelton JB, Lewis MS, Beenhouwer DO, Chamie K, Rose BS, Maxwell KN, Nickols NG, Yamoah[...]